Literature DB >> 34896031

Remote heart failure management using the HeartLogic algorithm. RE-HEART registry.

Javier de Juan Bagudá1, Juan J Gavira Gómez2, Marta Pachón Iglesias3, Rocío Cózar León4, Vanessa Escolar Pérez5, Óscar González Fernández6, Nuria Rivas Gándara7, Josebe Goirigolzarri Artaza8, Beatriz Díaz Molina9, Alfonso Macías Gallego10, Virgilio Martínez Mateo11, Juan G Martínez Martínez12, Natalia Marrero Negrín13, Gonzalo L Alonso Salinas14, Luis González Torres15, Juan F Delgado Jiménez16, Paula Sánchez-Aguilera3, Ernesto Díaz Infante4, María F Arcocha Torres5, Laura Peña Conde6, Ana B Méndez Fernández7, Nicasio Pérez Castellano8, José M Rubín López9, Inés Madrazo Delgado10, Manuel J Fernández-Anguita11, Pablo Ramos Ruiz17, Olga Medina Moreno13, David Cordero Pereda18, Carlos de Diego Rus15, Fernando Arribas Ynsaurriaga16, Ignacio García Bolao2, Rafael Salguero Bodes16.   

Abstract

INTRODUCTION AND
OBJECTIVES: HeartLogic is a multiparametric algorithm incorporated into implantable cardioverter-defibrillators (ICD). The associated alerts predict impending heart failure (HF) decompensations. Our objective was to analyze the association between alerts and clinical events and to describe the implementation of a protocol for remote management in a multicenter registry.
METHODS: We evaluated study phase 1 (the investigators were blinded to the alert state) and phases 2 and 3 (after HeartLogic activation, managed as per local practice and with a standardized protocol, respectively).
RESULTS: We included 288 patients from 15 centers. In phase 1, the median observation period was 10 months and there were 73 alerts (0.72 alerts/patient-y), with 8 hospitalizations and 2 emergency room admissions for HF (0.10 events/patient-y). There were no HF hospitalizations outside the alert period. In the active phases, the median follow-up was 16 (95%CI, 15-22) months and there were 277 alerts (0.89 alerts/patient-y); 33 were associated with HF hospitalizations or HF death (n=6), 46 with minor decompensations, and 78 with other events. The unexplained alert rate was 0.39 alerts/patient-y. Outside the alert state, there was only 1 HF hospitalization and 1 minor HF decompensation. Most alerts (82% in phase 2 and 81% in phase 3; P=.861) were remotely managed. The median NT-proBNP value was higher within than outside the alert state (7378 vs 1210 pg/mL; P <.001).
CONCLUSIONS: The HeartLogic index was frequently associated with HF-related events and other clinically relevant situations, with a low rate of unexplained events. A standardized protocol allowed alerts to be safely and remotely detected and appropriate action to be taken on them.
Copyright © 2021 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  Cardiac resynchronization therapy; DAI; Estratificación de riesgo; Heart failure; ICD; Insuficiencia cardiaca; Monitorización a distancia; Remote monitoring; Risk stratification; Terapia de resincronización cardiaca

Mesh:

Year:  2021        PMID: 34896031     DOI: 10.1016/j.rec.2021.09.015

Source DB:  PubMed          Journal:  Rev Esp Cardiol (Engl Ed)        ISSN: 1885-5857


  2 in total

Review 1.  Clinical Utility of HeartLogic, a Multiparametric Telemonitoring System, in Heart Failure.

Authors:  Juan Carlos López-Azor; Noelia de la Torre; María Dolores García-Cosío Carmena; Pedro Caravaca Pérez; Catalina Munera; Irene MarcoClement; Rocío Cózar León; Jesús Álvarez-García; Marta Pachón; Fernando Arribas Ynsaurriaga; Rafael Salguero Bodes; Juan Francisco Delgado Jiménez; Javier de Juan Bagudá
Journal:  Card Fail Rev       Date:  2022-04-21

2.  Implantable Cardioverter Defibrillator Multisensor Monitoring during Home Confinement Caused by the COVID-19 Pandemic.

Authors:  Matteo Ziacchi; Leonardo Calò; Antonio D'Onofrio; Michele Manzo; Antonio Dello Russo; Luca Santini; Giovanna Giubilato; Cosimo Carriere; Vincenzo Ezio Santobuono; Gianluca Savarese; Carmelo La Greca; Giuseppe Arena; Antonello Talarico; Ennio Pisanò; Massimo Giammaria; Antonio Pangallo; Monica Campari; Sergio Valsecchi; Igor Diemberger
Journal:  Biology (Basel)       Date:  2022-01-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.